The reason the progress may seem slow is a good one though. It's because the existing vaccines are working well. As soon as you change a formulation you've got an issue, do you make only the new stuff, or do you make the old stuff as well.Thanks for the replies. Interesting stuff, but slower progress than I'd hoped for.
For Pfizer who've shipped massive numbers of vaccines, the changeover will cost production time as well as need a lot of testing. Getting it wrong, and producing a less efficacious vaccine against new variants than we've already got, would kill more people than it saves. Getting it right (for Delta and beta) might be irrelevant within months, and the production blip (or worse) could easily slow down rollout and kill more people than any temporarily improved efficacy saves.
The bigger research story is focused on things like booster cocktails, combined flu/covid jabs etc. Those won't appear overnight.
If we'd "really" already seen that we needed a new formulation for the autumn (and knew which mutation to target) I'm pretty confident we'd have got one. As things stand Pfizer in particular are more interested in the danger of poor immunity in some immune suppressed people and possible waning immunity against infection in more people (based on some very early data from Israel).